N@N

Array BioPharma Announces Abstracts Selected for Presentation at 2010 ASCO Annual Meeting

^{Published on 2010-05-20 15:35:14 - Market Wire}
 

BOULDER, Colo.--([ BUSINESS WIRE ])--Array BioPharma Inc. (NASDAQ: ARRY) today announced that four abstracts have been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held from June 4-8, 2010, in Chicago, Illinois. Presentations will disclose new findings about its anti-cancer programs: AZD6244 (ARRY-886), a MEK inhibitor licensed to AstraZeneca PLC and ARRY-520, a KSP inhibitor.

The abstracts can be accessed through the ASCO website, [ www.asco.org ]. Abstract titles are provided below; however, please note that according to ASCO policy, all data is embargoed until the time of the beginning of the presentation. The ARRY-520 poster and presentation will be available as PDFs after they are presented on Array's website at [ www.arraybiopharma.com ].

AZD6244 (ARRY-142886) / MEK Inhibitor:

• Abstract #5536 (June 4, 2:00 a" 6:00 p.m. CT; S403): Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements
• Abstract #8501 (June 5, 4:45 p.m. CT; S406): Clinical responses to AZD6244 (ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma

ARRY-520 / KSP Inhibitor

• Abstract #8132 (June 5, 8:00 a" 12-noon CT, S Hall A2): Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM)
• Abstract #2570 (June 7, 8:00 a" 12-noon CT, S Hall A2): A Phase I study of ARRY-520 in solid tumors

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. For more information on Array, please go to [ www.arraybiopharma.com ].

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our potential to earn future milestone and royalty payments under our collaboration agreements, the potential for the results of ongoing preclinical and clinical trials to support regulatory approval or the marketing success of a drug candidate, our ability to partner our proprietary drug candidates for up front fees, milestone and/or royalty payments, and our future plans to progress and develop our proprietary programs. These statements involve significant risks and uncertainties, including those discussed in our most recent annual report filed on form 10-K, in our quarterly reports filed on Form 10-Q, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research and development efforts and to create effective, commercially viable drugs; our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials; risks associated with our dependence on third-party service providers to successfully conduct clinical trials within and outside the United States; our ability to achieve and maintain profitability and maintain sufficient cash resources; the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities; our ability to out-license our proprietary candidates on favorable terms; risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates; the ability of our collaborators and of Array BioPharma Inc. to meet objectives tied to milestones and royalties; our ability to attract and retain experienced scientists and management. We are providing this information as of May 20, 2010. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.